5-MeO-DET

5-MeO-DET
Clinical data
Other names	5-Methoxy-N,N-diethyltryptamine
Routes of; administration	Oral, smoking
Drug class	Serotonin receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
ATC code	None;
Legal status
Legal status	DE: NpSG (Industrial and scientific use only); UK: Class A;
Pharmacokinetic data
Onset of action	Oral: 20–30 minutes; Smoking: A few minutes
Duration of action	Oral: 3–4 hours; Smoking: 1.5 hours
Identifiers
	IUPAC name N,N-diethyl-2-(5-methoxy-1H-indol-3-yl)ethanamine;
CAS Number	1218-40-2 ;
PubChem CID	417608;
ChemSpider	369669 ;
UNII	52HU7LM8HL;
ChEMBL	ChEMBL342986 ;
CompTox Dashboard (EPA)	DTXSID30329130 ;
Chemical and physical data
Formula	C15H22N2O
Molar mass	246.354 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCN(CC)CCc1c[nH]c2ccc(OC)cc12;
	InChI InChI=1S/C15H22N2O/c1-4-17(5-2)9-8-12-11-16-15-7-6-13(18-3)10-14(12)15/h6-7,10-11,16H,4-5,8-9H2,1-3H3 ; Key:KGDVJQQWCDDEPP-UHFFFAOYSA-N ;
	(verify)

5-MeO-DET, also known as 5-methoxy-N,N-diethyltryptamine is a psychedelic drug of the tryptamine family related to 5-MeO-DMT. It is taken orally but can also be used parenterally.

The drug produces strong side effects such as lightheadedness, dizziness, and vertigo at low doses that prevent hallucinogenic doses from being tolerated or used. It acts as a serotonin receptor modulator, including as an agonist of the serotonin 5-HT_2A receptor. 5-MeO-DET produces psychedelic-like effects in animals. Analogues of 5-MeO-DET include 5-MeO-DMT, 5-MeO-DPT, dipropyltryptamine (DPT), and 4-HO-DPT (deprocin), among others.

5-MeO-DET was first described in the literature by 1968. It was further described by Alexander Shulgin in his 1997 book TiHKAL (Tryptamines I Have Known and Loved). The drug was encountered as a novel designer drug in 2005.